BVS Stock — Bioventus Inc

Bioventus Inc (BVS)

Updated October 16, 2026.

BVS is a Stock. Total return is -30.8% over the past 5.7 years, 141.7 points behind SPY at 110.9%.

Bioventus Inc. is a medical device company that develops and sells pain relief and musculoskeletal therapy products, including intra-articular injections for osteoarthritis, peripheral nerve stimulation devices, ultrasonic surgical systems for bone and soft tissue procedures, and bone graft substitutes for orthopedic and spinal applications. The company does not currently have a known distribution policy. Bioventus may appeal to investors seeking exposure to the medical device sector, though it operates as a growth-oriented company rather than an income-generating investment.

BVS performance versus SPY

Price and return data through 2026-10-16.

Total return is -30.8% over the past 5.7 years, 141.7 points behind SPY at 110.9%. Over the past year its total return — price change plus distributions reinvested — is 93.3%. Its deepest 1-year drawdown was 27.5%.

BVS key facts

Asset type

Stock

Asset class

Equity

Inception date

02/11/2021

Distribution frequency

None

Last close

$13.30 (as of 2026-10-16)

Market cap

$908,458,402

Average volume

332925.0

Beta

0.642

Payout ratio

0.0%

P/E ratio

17.05

Forward P/E

14.7929

EPS

$0.78

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

BVS risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 27.5%.

Who may consider BVS — and who may not

It is a weaker fit for investors who need monthly cash flow (BVS does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on BVS

• All tickers starting with B

Tagged: Healthcare.

Frequently asked questions